BI 907828, Ezabenlimab, BI 907828, BI 907828 clinical trials

EMPIRE : Targeting MDM2 and PD1 in tumors with tertiary lymphoid structures

This study is looking into new ways to treat advanced solid cancers. It's testing a combination of medicines (BI 907828 and Ezabenlimab) to see if they can help control the cancer's growth in adult patients. Researchers want to understand how well these drugs work.